3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thymoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thymoma
×
selinexor
×
Thoracic
×
Clear all
NCT03193437
2023-02-16
SELECT
Georgetown University
Phase 2
Terminated
8 enrolled
11 charts
NCT03466827
2018-03-15
TET-SEL
Rigshospitalet, Denmark
Phase 2
Unknown
25 enrolled